The Institute for Clinical and Economic Review (ICER) on Thursday released a draft evidence report assessing the comparative clinical effectiveness and value of cystic fibrosis transmembrane conductance regulator (CFTR) modulators, including combination therapies tezacaftor/ivacaftor (Symdeko, Vertex Pharmaceuticals) and lumacaftor/ivacaftor (Orkambi, Vertex Pharmaceuticals), as well as the monotherapy ivacaftor (Kalydeco, Vertex Pharmaceuticals), for the treatment of cystic fibrosis.
ICER is committed to engaging with all stakeholders in a thorough and transparent manner. Prior to conducting this review, ICER spoke with key patient groups, clinical experts, and manufacturers, and accepted public comments on a Draft Scoping Document. The current draft report incorporates input received from patients, clinicians, and other stakeholders during each of these opportunities for engagement.
The report and draft voting questions are now open to public comment until 5 p.m. April 12. All stakeholders are invited to submit formal comments by email to email@example.com.
To read the full press release, click here.